Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719

Sionna Therapeutics, Inc.

2026-Q1 EPS reported -$0.60

Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.
Cash and equivalents $289.9M; expected to fund operations into 2028.
Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.
Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sionna Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.8 million.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $26.8 million
Result: reported results

Exact text from the filing

Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the three months ended March 31, 2026.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Sionna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-033870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.